We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Transmedics Group Inc (TMDX) NPV

Sell:$83.74 Buy:$83.86 Change: $2.17 (2.66%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $2.17 (2.66%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $2.17 (2.66%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

TransMedics Group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. It has designed and developed an organ care system (OCS), a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It designed its OCS technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state. It has developed OCS products, one each for lung, heart and liver transplantation. Its products include OCS Heart, OCS Lung and OCS Liver. Its OCS product consists of three components customized for each organ, which include the OCS Console, OCS Perfusion Set and OCS Solutions. The Company is also a provider of air logistics dedicated to organ transplantation in the United States.

Contact details

200 Minuteman Road
United States
+1 (978) 5520900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.68 billion
Shares in issue:
32.72 million
Health Care Equipment
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Waleed Hassanein
    President, Chief Executive Officer, Director
  • Stephen Gordon
    Chief Financial Officer, Treasurer, Secretary
  • Anil Ranganath
    Senior Vice President, General Counsel, Company Secretary
  • Nick Corcoran
    Senior Vice President - Supply Chain and Operations
  • Laura Damme
    Vice President - Clinical Affairs
  • Miriam Provost
    Vice President - Global Regulatory Affairs
  • Tamer Khayal
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.